Exactly. AMBS silence completely explains it in my opinion. Even Gerald has previously said that he can't comment on certain things with Lympro. If AMBS is selling Lympro then it makes no sense to publicly communicate revenue numbers during negotiations. Any shareholder that demands it really is not a good steward of their investment because it would negatively impact the eventual deal.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links